Nivolumab in renal cell carcinoma

Ortega, Rosa M. Michel; Drabkin, Harry A.

doi:10.1517/14712598.2015.1049596

Cited by 4 publications

(2 citation statements)

References 60 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are seven targeted therapies currently available for clear cell RCC: VEGFR TKIs (sorafenib, sunitinib, pazopanib, and axitinib); VEGF-directed monoclonal antibody bevacizumab (approved in combination with IFN); and mTORi (everolimus and temsirolimus). Although these agents achieved a positive impact, long-term responders are rare ( 21 ). High-dose IL-2 is the only approved agent to produce complete durable responses, but hospitalization and intense monitoring are still required ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Gamulin¹,

Nham²,

Rkman³

et al. 2020

Croat Med J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Gamulin¹,

Nham²,

Rkman³

et al. 2020

Croat Med J

View full text Add to dashboard Cite

“…In addition, the high immunogenicity of RCC has led to the implementation of various immunotherapeutic approaches. In the setting of adjuvant immunotherapy, the long-term use of the cytokines interleukin (IL)-2 [7] and IFNα [8] has been extended to IL-21 [9], while in parallel new immune modulators have been developed, such as check point inhibitors acting on the PD1/PDL1 axis [10]. In the setting of active immunotherapy patients have been vaccinated with “undefined” tumor specificities using autologous or allogeneic tumor cells whose immunogenicity has been enhanced by transfection of immune stimulatory molecules [11–13], IFNγ treatment [14] or by loading their lysate / fusing them with dendritic cells (DC) [15–17].…”

Section: Introductionmentioning

confidence: 99%

Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients

et al. 2017

View full text Add to dashboard Cite

A major requirement for cancer immunotherapy is the development of biomarkers for prognosis and for monitoring therapy response. In an attempt to evaluate the immune response of renal cell carcinoma (RCC) patients, tumor lesions and / or blood samples from 12 RCC patients underwent deep T cell receptor (TCR) sequencing. Despite the low number of samples, different TCR distribution patterns could be detected. Most of the RCC patients presented "patient-specific" TCR sequences, and those clonotypes were present at higher frequency in tumor lesions suggesting a specific extravasation from the blood. Comparison among the tumor samples revealed also "patient-shared" TCR patterns. Indeed, a central core of 16 different TCRs were shared by 3 patients, whereas other 6 patients shared between 4 and 6 TCR sequences, with two sub-groups sharing 12 to 17 different clonotypes. The relative frequencies of shared clonotypes were very different varying from < 1% to a maximum of 37% of the total TCR repertoire. These data confirm the presence of tumor-specific TCR within the cancer tissue and suggest the existence of shared epitopes among different patients that might be used as targets for tumor immunotherapy.

show abstract

Newly-presented potential targeted drugs in the treatment of renal cell cancer

Zhang

Zheng

2016

Open Life Sciences

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most frequent form of renal cancer, and is associated with a high frequency of metastasis. While, there is few therapeutic methods can substantially prolong survival. Superior to cytokine therapy with IL-2 and/or IFN-α, several newer targeted treatments are available for the treatment of patients with advanced conventional (clear cell) renal cell carcinoma (RCC), which received improved outcomes. These newer targeted treatments include the multi-targeted tyrosine kinase inhibitors (TKIs, sorafenib, sunitinib, pazopanib, and axitinib), the humanised antivascular endothelial growth factor (VEGF) monoclonal antibody [bevacizumab combined with interferon (IFN)-α], and mTOR (mammalian target of rapamycin) complex 1 kinase inhibitors (everolimus and temsirolimus). However, these targeted drugs are still associated with limited efficacy and high toxicity, so there is still a strong need for further discovery of new targeted drugs. In the present manuscript, we summarize newly-presented potential targeted drugs for RCC, classified by drug characteristic, small molecule, small molecule combination, monoclonal antibody, polysaccharides, organometals and peptides.

show abstract

Nivolumab in renal cell carcinoma

Cited by 4 publications

References 60 publications

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients

Newly-presented potential targeted drugs in the treatment of renal cell cancer

Contact Info

Product

Resources

About